Micregen has focused out of the public eye for seven years, developing what we believe to be a paradigm shift in stem cell science, that has the potential to be a most disruptive medical innovation.
The founder’s lifetime work, in cutting-edge biological regenerative medicine, has already saved lives and world-famous sporting careers.
We are harnessing this ground breaking experience to develop therapeutics for multiple degenerative and inflammatory conditions, with a strategic goal of enabling ‘healthy-ageing’.
The first in human (FIH) clinical trials are scheduled for the early 2020’s. Micregen is a UK, privately funded company, with clean cap table and no debt. Our team is small and world class.